Immunotherapy of cancer by IL-12-based cytokine combinations
about
Interleukin 12: still a promising candidate for tumor immunotherapy?Understanding of molecular mechanisms in natural killer cell therapyReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionSystemic IL-12 administration alters hepatic dendritic cell stimulation capabilitiesAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaElectroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developmentsPolyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against Listeria monocytogenes: Insights from a DC vaccination model.Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hostsNew insights into IL-12-mediated tumor suppression.Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum.Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Ustekinumab: differential use in psoriasisBleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancerTherapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines.Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic CellsEnhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study.Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in MiceThe p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production.Differential control of Helios(+/-) Treg development by monocyte subsets through disparate inflammatory cytokinesTumor Cell Clone Expressing the Membrane-bound Form of IL-12p35 Subunit Stimulates Antitumor Immune Responses Dominated by CD8(+) T CellsSusceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.Collapse of the tumor stroma is triggered by IL-12 induction of Fas.IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapyCancer prevention and therapy through the modulation of the tumor microenvironment.Gene-modified bone marrow cell therapy for prostate cancer.Surgery as a double-edged sword: a clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses.Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells.Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironmentPretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.Dysregulation of the immune system caused by silica and asbestos.Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members.
P2860
Q26861559-CE8E37D5-2CD3-4A21-813C-0658EB97519DQ28086976-06CDE8E4-06C8-40E5-A185-E88C20EA496FQ28280687-82698053-AA96-49F6-B6CE-65E74B4FA723Q28383385-15258C18-480D-4FAC-A6B2-9EB0B44EC0DCQ28512535-26C323B6-A444-46F3-A6CF-B62E4863E547Q28749871-82FCBD91-F1F1-4A64-97AF-70CDE5694AF1Q33713435-83C34FD7-84DD-417F-A5D7-9831B78F41D4Q33784707-75F9F9DA-094B-4D55-9AFC-F36BE07499E3Q33987288-9F8BCFFA-5978-4C2A-B1B5-2BB3022BC44FQ34109953-917CE228-917B-4664-998F-9A8135A42F20Q34436897-7B934CE2-F58C-46F1-8D8C-CFDBD4E25390Q34452728-F08E53A3-BA8B-441B-896B-38B9AFB26A78Q34757266-9F35746B-5A62-47E2-A531-1597E8160954Q35096980-95BE25C5-D96A-40C7-B807-D0C9CFDB52FCQ35140904-5DFBDD69-553B-45BD-B28B-83D127385C20Q35578622-2706CC8C-7C3D-48AD-9CAE-42D286EA555BQ35582297-CF0785A8-EB83-44F0-8A2E-A68199C13927Q35690511-7ACF7575-3C78-4CCF-9655-FBED700C016BQ35741852-E25FEABC-275D-4016-9C04-2E2F118789CAQ35766493-94C71F6E-A2C3-4572-9FEF-DC462A3801F2Q35888942-276D01F6-1279-4D88-A36B-D2AF0A96ADC5Q36038020-2083594A-0345-4AC8-919D-355EAF76D088Q36092102-50B7161F-EC43-49DD-B338-CDA242CC1AABQ36249314-2A3140A4-867D-4AA7-A894-5AB4005A8453Q36647429-18C78AF8-17D2-4C8E-A183-D87302FA47AEQ36730422-BC7BD651-B9AC-45A0-9D8A-42B1947DD9D3Q36859939-E42E16A5-C839-450C-85EE-71544014A9B8Q36928622-39691C62-59F2-4C70-82BB-5FA51DAC0B6DQ36984473-E1884FE0-A922-49A0-8B77-BF9BDE0ECFF2Q37041732-F6111608-5C66-4E71-BC1F-2F85A4850F42Q37058267-FD1CCDF6-6F37-49AF-95BE-34F03270AF59Q37127252-831601DA-0F9B-4619-8826-2EFC71A07BD2Q37342761-0C70EDD0-9D82-452D-AB14-41DA3C51E68DQ37389753-69C9555C-31BC-4B8B-B211-C3E921245939Q37439660-F2D31027-CEE4-4020-A364-CE0329ACDC1BQ37464945-DD93AB95-7B51-493F-98B7-E78A856ABA08Q37551110-B101B38F-6F32-47AC-9EB1-3CB7BCE6C798Q37706248-3635A28C-A788-44DE-AE58-DD7E3DD76E54Q37789761-19D29390-F67E-4076-B96F-E73CFDE60856Q37793235-CA98C9BE-80F4-48FB-B1E0-97E9DF1CC46B
P2860
Immunotherapy of cancer by IL-12-based cytokine combinations
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunotherapy of cancer by IL-12-based cytokine combinations
@ast
Immunotherapy of cancer by IL-12-based cytokine combinations
@en
type
label
Immunotherapy of cancer by IL-12-based cytokine combinations
@ast
Immunotherapy of cancer by IL-12-based cytokine combinations
@en
prefLabel
Immunotherapy of cancer by IL-12-based cytokine combinations
@ast
Immunotherapy of cancer by IL-12-based cytokine combinations
@en
P2093
P2860
P1476
Immunotherapy of cancer by IL-12-based cytokine combinations
@en
P2093
Jeff J Subleski
Jon M Wigginton
Jonathan M Weiss
Robert H Wiltrout
P2860
P304
P356
10.1517/14712598.7.11.1705
P407
P577
2007-11-01T00:00:00Z